 The FDA released its briefing documents for the advisory committee to discuss Amylyx Pharmaceuticals Incs NASDAQ: AMLX sodium phenylbutyratetaurursodiol AMX0035 powder for amyotrophic lateral sclerosis ALS. Agency statisticians called into question the Companys. 